Navigation Links
Arpida Reports Progress in Pivotal Phase III Trial With TLT Treatment in Onychomycosis
Date:1/22/2008

. It can cause pain, discomfort, and disfigurement and may produce serious physical and occupational limitations. It is one of the most common dermatological diseases, affecting an estimated 30 million people in the USA alone while prevalence is steadily increasing for various reasons, e.g. the aging of the population, diabetes etc.

Oral therapies that are effective for treating OM include Novartis's Lamisil (R) (terbinafine) and J&J's Sporanox(R) (itraconazole). However, patients are reluctant to adopt this systemic modality for an essentially superficial disease particularly in view of lengthy treatment times and concerns regarding potential toxicity and side effects.

Approved topical treatments for OM include ciclopirox lacquer (Sanofi-Aventis's Batrafen(R) in EU; Penlac(R) in the US) and amorolfine lacquer (Galderma's Loceryl(R); EU), however, both drugs show low efficacy primarily due to the poor bioavailability in the nail bed. A safe and effective topical treatment would be expected to gain a significant market share as it would satisfy a medical need coupled with a strong patient demand.

Total revenues in this indication are ca. USD 2 billion per year and are forecast to grow based on the increasing prevalence of OM. Moreover, due to a lack of effective topical treatments and issues inherent to long term use of oral treatments, a large proportion of patients remain untreated and consequently the addressable potential market is much larger. Novartis's Lamisil(R) is the current market leader with revenues of USD 978 million in 2006.

About Arpida Ltd.

Arpida (SWX: ARPN) is a biopharmaceutical company with research facilities in Reinach, Switzerland and in the USA. It focuses on the discovery and development of novel drugs that seek to overcome the growing problem of microbial resistance. The most advanced compounds include an antibacterial in an NDA-filing process and an antifungal in Phase III.

Arpida's leading product
'/>"/>

SOURCE Arpida Ltd
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Arpida Interim Results for six Months to 30 June 2007
2. Arpida Invited to Present Preclinical Data on Novel Topical Antibiotic AR-2474 at ICAAC
3. Arpida Presents Preclinical and Clinical Data on Iclaprim at ICAAC
4. Arpida Presents Preclinical Data on AR-2474 at ICAAC
5. Arpida Presents Data on Iclaprim at Scientific Congress in Germany
6. Arpida-Supported CME Symposium Available Online
7. Arpida Receives Green Light From US FDA for Phase II Efficacy Trial With Oral Iclaprim
8. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
9. QMed, Inc. Reports July Medicare SNP Enrollments
10. Phlo Affiliate Reports Expanded Coverage to Oregon Border
11. Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... Due to a misstatement posted by the ... Cell Technology Center, LLC ( ASCTC ) was reported as ... that might benefit ALS patients. Because of ASCTC's exclusive ... technologies and therapeutic applications, FRC listed ASCTC as one of ... who wish not to support research that requires the death ...
(Date:8/28/2014)... 28, 2014 Best Sanitizers, Inc., a ... food processing industry, is asking industry professionals to prepare ... of the E2 soap they’re currently using to the ... . Hand hygiene is critical to fighting cross-contamination ... environment. Six key criteria are identified to evaluate the ...
(Date:8/28/2014)... devices in spintronics, an electronic which is not ... also on their spin and the spin-related magnetism. ... magnetic signals and vice versa. Recently, the research ... of Physics at Johannes Gutenberg University Mainz in ... Japan, has for the first time realised a ...
(Date:8/28/2014)... SunTrust Robinson Humphrey (STRH) today announced the ... research team in biotechnology and oilfield services.  ... demonstrates our commitment to providing our valued institutional ... decision making," said Biff Woodruff , Head ... significant investments in differentiated content at a time ...
Breaking Biology Technology:The Adult Stem Cell Technology Center, LLC Declines ALS Ice Bucket Challenge Donors Wishing to Support Ethical Research for New Stem Cell Therapies 2The Adult Stem Cell Technology Center, LLC Declines ALS Ice Bucket Challenge Donors Wishing to Support Ethical Research for New Stem Cell Therapies 3Best Sanitizers, Inc. Asks Food Industry Professionals: With Fall Harvest On the Way, Is Your E2 Hand Soap Up to the Task? 2A new, tunable device for spintronics 2A new, tunable device for spintronics 3SunTrust Robinson Humphrey Expands Equity Research in Healthcare and Energy 2SunTrust Robinson Humphrey Expands Equity Research in Healthcare and Energy 3
(Date:8/28/2014)... at the University of Minnesota have developed an animal ... used for muscle regeneration research as well as studies ... The research is published in the current edition of ... no treatment for FSHD, which is thought by many ... FSHD is an unusual genetic disorder because, unlike most ...
(Date:8/28/2014)... compounds that could positively impact the global ... possible, thanks to researchers in Penn State,s ... suppository made from the seaweed-derived food ingredient ... Tenofovir provides a woman-initiated, drug-delivery vehicle that ... transmitted infections during unprotected heterosexual intercourse, the ...
(Date:8/28/2014)... new roads will be built worldwide by 2050. Many ... where they bring an influx of destructive loggers, hunters ... has created a ,global roadmap, for prioritising road building ... demands of development and environmental protection. , The map ... natural importance of ecosystems and a ,road-benefits, layer that ...
Breaking Biology News(10 mins):UMN researchers find animal model for understudied type of muscular dystrophy 2Sensory-tested drug-delivery vehicle could limit spread of HIV, AIDS 2Sensory-tested drug-delivery vehicle could limit spread of HIV, AIDS 3Study shows where on the planet new roads should and should not go 2Study shows where on the planet new roads should and should not go 3
... Hamilton, Nov. 11, 2013 Researchers at McMaster University have ... and it may serve as a way to measure injury. ... muscle damage biomarker," said Thomas Hawke, principal investigator and an ... at McMaster. "Regardless of the way in which ...
... after giving birth plays a big factor in the quantity and ... University of Missouri have found that subclinical hypocalcemia, which is the ... occurs in many cows after giving birth, is related to higher ... the MU College of Veterinary Medicine, says these higher levels of ...
... his sons less sensitive to the drug and thereby more ... animal study presented by Penn Medicine researchers at Neuroscience 2013, ... The study, led by Mathieu Wimmer, PhD, a post-doctoral researcher ... of Neuroscience in Psychiatry at the Perelman School of Medicine ...
Cached Biology News:Low levels of blood calcium in dairy cows may affect cow health and productivity, MU study finds 2Sons of cocaine-using fathers may resist addiction to drug, Penn Medicine study suggests 2
Mouse monoclonal [AZ24] to Polo like kinase ( Abpromise for all tested applications)....
... brings together two mature, well-understood technologies: ... surfaces. This combination produces a sensitive ... detection of molecular binding events without ... Protein-specific capture molecules are immobilized on ...
... LabWorks Software provides a comprehensive experiment based ... drop down menus yet sophisticated and powerful ... dozens of CCD cameras for easy image ... , Automated Digital Video Playback ...
RABBIT ANTI HUMAN ALPHA-2-ANTIPLASMIN...
Biology Products: